Pradofloxacin

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H21FN4O3
Molecular Weight	396.4148
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CN(C2CC2)C3=C(C=C(F)C(N4C[C@@H]5CCCN[C@@H]5C4)=C3C#N)C1=O

InChI

InChIKey=LZLXHGFNOWILIY-APPDUMDISA-N

InChI=1S/C21H21FN4O3/c22-16-6-13-18(26(12-3-4-12)9-15(20(13)27)21(28)29)14(7-23)19(16)25-8-11-2-1-5-24-17(11)10-25/h6,9,11-12,17,24H,1-5,8,10H2,(H,28,29)/t11-,17+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C21H21FN4O3
Molecular Weight	396.4148
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugs.com/vet/veraflox-pradofloxacin-tablets-60-mg-can.html

Pradofloxacin (trade name Veraflox) is a 3rd generation enhanced spectrum veterinary antibiotic of the fluoroquinolone class. It was developed by Bayer HealthCare AG, Animal Health GmbH, and received approval from the European Commission in April 2011 for prescription-only use in veterinary medicine for the treatment of bacterial infections in dogs and cats. The primary mode of action of fluoroquinolones involves interaction with enzymes essential for major DNA functions such as replication, transcription, and recombination. The primary targets for Pradofloxacin are the bacterial DNA gyrase and topoisomerase IV enzymes. Reversible association between Pradofloxacin and DNA gyrase or DNA topoisomerase IV in the target bacteria results in inhibition of these enzymes and rapid death of the bacterial cell. The rapidity and extent of bacterial killing are directly proportional to the drug concentration.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial DNA gyrase 66 Target ID: CHEMBL2311224 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/000159/WC500109014.pdf	Inhibitor 8504
Topoisomerase IV 62 Target ID: CHEMBL2363076 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/000159/WC500109014.pdf	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Wound infection 4 Sources: https://www.drugs.com/vet/veraflox-pradofloxacin-tablets-60-mg-can.html	Curative	Approved 8583	Veraflox Approved Use Unknown
Pyoderma 4 Sources: https://www.drugs.com/vet/veraflox-pradofloxacin-tablets-60-mg-can.html	Curative	Approved 8583	Veraflox Approved Use Unknown
Urinary tract infections 207 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/000159/WC500109014.pdf	Curative	Approved 8583	Veraflox Approved Use Unknown

PubMed

Title	Date	PubMed
Studies on a new device for drug delivery to the eye.	2005 Feb	15661500
In vivo tolerance and kinetics of a novel ocular drug delivery device.	2006 Nov 28	17718964
Pradofloxacin in the treatment of canine deep pyoderma: a multicentred, blinded, randomized parallel trial.	2007 Jun	17470228
Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats.	2007 Nov	17872918
Clinical efficacy and palatability of pradofloxacin 2.5% oral suspension for the treatment of bacterial lower urinary tract infections in cats.	2007 Sep-Oct	17939554
Identification of Qnr and AAC(6')-1b-cr plasmid-mediated fluoroquinolone resistance determinants in multidrug-resistant Enterobacter spp. isolated from extraintestinal infections in companion animals.	2010 Jul 14	20036084
Molecular mechanisms of Bartonella henselae resistance to azithromycin, pradofloxacin and enrofloxacin.	2010 Mar	20022937
Haemotropic mycoplasmas: what's their real significance in cats?	2010 May	20417898
Fluoroquinolone resistance mechanisms in multidrug-resistant Escherichia coli isolated from extraintestinal infections in dogs.	2010 Nov 20	20471187
Evaluation of the clinical efficacy of pradofloxacin tablets for the treatment of canine pyoderma.	2010 Sep-Oct	20810550

Patents

Sample Use Guides

In Vivo Use Guide

Administer 3.0 mg/kg bodyweight of pradofloxacin once daily.

Route of Administration: Oral

In Vitro Use Guide

The MIC of pradofloxacinc was determined by broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) standards,6 within the concentration range 0.008–16 μg/mL. The MICs of enrofloxacin and ciprofloxacin were determined using commercial stripsd on Mueller–Hinton 2 agar inoculated with a bacterial suspension (density of 0.5 McFarland) and incubated for 24 h at 35°C. The reference strain S. aureus ATCC 25923 was used as a quality control for MIC determination with the commercial strips, according to the manufacturer’s instructions.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:33:27 GMT 2025` Edited by `admin` on `Wed Apr 02 07:33:27 GMT 2025`
Record UNII	6O0T5E048I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Pradofloxacin

Official Name

English

PRADOFLOXACIN [MI]

Preferred Name

English

8-Cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid

Systematic Name

English

PRADOFLOXACIN [EMA EPAR VETERINARY]

Common Name

English

3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-

Systematic Name

English

PRADOFLOXACIN [GREEN BOOK]

Common Name

English

VERAFLOX

Brand Name

English

pradofloxacin [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ01MA97